Noguchi Masanori, Koga Noriko, Igawa Tsukasa, Itoh Kyogo
Clinical Research Division, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan.
Department of Urology, Kurume University School of Medicine, Kurume, Japan.
Int J Urol. 2017 Sep;24(9):675-680. doi: 10.1111/iju.13397. Epub 2017 Jun 21.
Prostate cancer is the most common cancer in men, and the second leading cause of cancer-related death in Western countries. Prostate cancer-related death occurs in patients with metastatic castration-resistant prostate cancer. Although several new drugs for castration-resistant prostate cancer have been approved, each of these has prolonged survival by just a few months. Consequently, new therapies are sorely needed. Recently, it has been recognized that immunotherapy is an effective treatment for prostate cancer patients. Several strategies, such as cancer vaccines and immune checkpoint inhibitors, have been investigated in clinical studies for prostate cancer patients. In the present review, the results of the most recent clinical studies investigating immunotherapy in prostate cancer patients are reported, and the future clinical development of immunotherapy for prostate cancer is discussed.
前列腺癌是男性中最常见的癌症，也是西方国家癌症相关死亡的第二大主要原因。前列腺癌相关死亡发生在转移性去势抵抗性前列腺癌患者中。尽管几种用于去势抵抗性前列腺癌的新药已获批准，但每种药物仅将生存期延长了几个月。因此，迫切需要新的治疗方法。最近，人们认识到免疫疗法是前列腺癌患者的一种有效治疗方法。几种策略，如癌症疫苗和免疫检查点抑制剂，已在前列腺癌患者的临床研究中进行了调查。在本综述中，报告了最近调查前列腺癌患者免疫疗法的临床研究结果，并讨论了前列腺癌免疫疗法的未来临床发展。
